Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 22nd Century Group, Inc.XXII · Entity 8519 | Chief Legal Officer & Secy. | March 14, 2023 | March 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
22nd Century Group, Inc.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,972 |
Reported balance
After 2023-03-14 transaction · row 1
1 source rowRow 1 · 2023-03-14 · Grant · Acquired 308,972 · Balance 308,972 F1: The restricted stock units vest 1/3 per year on March 14, 2024, 2025, and 2026; subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest 1/3 per year on March 14, 2024, 2025, and 2026; subject to continued service with the Company.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOTELEMETRY, INC.
Report date December 31, 2019 · Filed January 06, 2020
Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,507 |
Ending reported balance
After 2019-12-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-12-31 · Exercise / conversion · Acquired 1,632 · Balance 10,139 Row 2 · 2019-12-31 · Exercise / conversion · Acquired 3,433 · Balance 13,572 Row 3 · 2019-12-31 · Sale · Disposed 5,065 · Balance 8,507 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.25 to $46.92, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.65 · Expires 2027-02-14 | Direct | 1,633 |
Reported balance
After 2019-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-31 · Exercise / conversion · Disposed 1,632 · Balance 1,633 F3: The stock options vested at the rate of 25% on each of December 31, 2017, 2018 and 2019. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.57 · Expires 2026-02-15 | Direct | 0 |
Reported balance
After 2019-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-31 · Exercise / conversion · Disposed 3,433 · Balance 0 F4: The stock options vested at the rate of 25% on each of December 31, 2016, 2017, 2018 and 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.25 to $46.92, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: The stock options vested at the rate of 25% on each of December 31, 2017, 2018 and 2019.
F4: The stock options vested at the rate of 25% on each of December 31, 2016, 2017, 2018 and 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2016 Filed Sep 7, 2016 19:32 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | Exercise / conversionCommon Stock | 1,241 | $2.54 | $3,152.14 |
DisclosureSEC source: 0001104659-16-143564 · a4.xml · nonDerivative · entry 2 Ferola Peter · CIK 0001465497 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 19:32 UTC | BIOTELEMETRY, INC. BEAT · Entity 142764 | SaleCommon Stock | 3,615 | $18.75 | $67,781.25 |
DisclosureSEC source: 0001104659-16-143564 · a4.xml · nonDerivative · entry 1 Ferola Peter · CIK 0001465497 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,637 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.60 to $18.91, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.